Platelet-rich plasma in dermatology

Plasma rico em plaquetas em dermatologia

INTRODUCTION

The use of Platelet-Rich Plasma (PRP) in medicine has become increasingly more widespread during the last decade. Most studies on the subject are carried out in areas such as orthopedics, sports medicine, and odontology. Only recently have articles relating to the dermatologic field begun to be published, where PRP has been used in order to promote accelerated wound healing and as an adjuvant treatment in rejuvenation, alopecia, and even following laser sessions.

The main objective of the present article is to describe what PRP is and to introduce some existing publications related to dermatology.

The authors have classified the publications according to the Oxford Centre for Evidence-Based Medicine’s guideline for levels of scientific evidence (LOE), criteria also adopted by the Brazilian Ministry of Health as a standard for the development of technical-scientific opinions (Chart 1).

ABSTRACT

The present article describes Platelet-Rich Plasma, with emphasis on its use in dermatology. The application of this procedure in medicine has become increasingly frequent during the last decade. Most publications on the topic arise from areas such as orthopaedics, sports medicine, and odontology. In the dermatologic field, Platelet-Rich Plasma has been used in order to promote accelerated wound healing, as an adjuvant treatment in rejuvenation and alopecia, and even after laser sessions. In the present review, the authors used articles published on the subject, attributing the Oxford Centre for Evidence Based Medicine’s “Level of Scientific Evidence” classification.

Keywords: blood platelets; dermatology; blood.
Platelet-rich plasma: what is this?

The term Platelet-Rich Plasma is a generic term used to describe a plasma suspension obtained from whole blood, prepared so as to contain platelet concentrations higher than those normally found in circulating blood. There is no consensus regarding which above-referenced concentration levels define the PRP—reference values used to define normality in the platelet count in blood is 1.5 to 4 x 10^5 platelets per ml).

A consensus on the appropriate values for classifying a plasma sample as PRP has not yet been reached among researchers, resulting in one of the difficulties found in the evaluation and comparison of results described in scientific articles. There are researchers concerned with obtaining a standardization for these blood derivatives taking into account quantities of components in the PRP, in addition to the platelets themselves.

It is known that PRP contains diverse concentrations of white and red cells, and that this may have an impact on the final outcome of the proposed treatment.

In 2008, the Brazilian Ministry of Health published a guide for the use of hemocomponents, where the platelet concentration used for transfusion should contain 1 x 10^7/μl.

Some studies diverge regarding cellular content and growth factors in PRPs obtained from the same individual when different methods are employed (e.g. one versus two centrifugation cycles). Such divergence was also found when different commercial kits were used in the preparation of blood samples. Significant differences in the PRP’s final result were also observed in the same individual who underwent successive blood collections.

There are a number of protocols described for obtaining PRP however all in general include a centrifugation process through which the different components of whole blood are separated according to their different densities. The protocols differ in time, speed, and number of centrifugations to which the whole blood is subjected. The volume of the initial blood sample and the types of collection tubes and anticoagulants used are also different for each method.

**Cellular components**

Platelets are anucleated fragments of megakaryocytes, and are produced in the bone marrow. They contain granules consisting of various substances, which are released upon activation of the platelets. Among the main substances that are released are growth factors (Chart 1), cytokines, adhesion molecules, integrins, and coagulation proteins.

As already mentioned, an important aspect to consider is the amount of erythrocytes and leukocytes in the obtained PRP.

There is disagreement as to the effect caused by leukocytes remaining in the PRP of the treated tissues. Some authors attribute an inflammatory effect—therefore a negative effect—to the presence of white cells in PRP while others attribute antibacterial and immune effects related to the presence of these cells. The current perception is that there are significant differences in the biological effects of PRP, according to its cellular content. Dohan et al. sought to group different PRP types according to their composition of leukocytes and fibrins. They suggest that the amount of white blood cells present in the PRP

**CHART 1: Growth factors in platelets**

<table>
<thead>
<tr>
<th>GROWTH FACTOR</th>
<th>BIOLOGICAL ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGF (Transforming Growth Factor) α e β</td>
<td>Proliferation and differentiation control of many cell types</td>
</tr>
<tr>
<td>PDGF (Platelet derived growth factor) α,β,C,D</td>
<td>Potent mitogen for connective tissue cells, inhibitor of apoptosis, increases the motility of mesenchymal cells, fibroblasts, endothelial cells, and neurons. May be involved in physiological processes and in diseases such as cancer and atherosclerosis</td>
</tr>
<tr>
<td>IGF I (Insulin-like growth factor I)</td>
<td>Promotes the mediation of the various effects of growth hormone</td>
</tr>
<tr>
<td>FGF I (Fibroblast growth factor I)</td>
<td>Induction of fibroblast proliferation and angiogenesis</td>
</tr>
<tr>
<td>EGF (Epidermal growth factor)</td>
<td>Induces the differentiation of cells and mitosis of cells of ecto and mesodermal origin</td>
</tr>
<tr>
<td>VEGF A, B e C (Vascular Endothelial growth factor)</td>
<td>Induces angiogenesis through the induction of mitosis in endothelial cells, and promotes alterations in vascular physiology and permeability</td>
</tr>
</tbody>
</table>

---

The definition of LOE employed in the present article takes into account the methods used in the studies and was elaborated with the aim of assisting physicians in making treatment decisions based on the available scientific literature.

Finally, it is important to emphasize that, in response to a request from ANVISA (the Brazilian National Health Surveillance Agency), the Brazilian Federal Council of Medicine (CFM) issued an opinion on the use of PRP in July 2011. The opinion was requested following media reports highlighting the effects of this therapy in orthopedics and dermatology. The opinion, which is available in its full version on the CFM’s website, states: “Platelet-rich plasma has been used by some physicians with varying results. Due to the variety of such results, it is not yet possible to define the degree of usefulness or approve definitively its use in therapeutic practice, thus it continues to be considered an experimental procedure.”

---

**Surg Cosmet Dermatol 2013;5(2):155-9.**
has a great influence on the release of growth factors. of the latter. This fact would have an impact on the biological effect of PRP’s, entailing difficulties in the comparison and evaluation of clinical results of patients treated with PRP’s of different compositions, for instance.

**Soluble components**

The activation of platelets causes the release of soluble factors present within their granules. Platelet activation depends on the adhesion of their surfaces to the molecules present on the damaged endothelium (von Willebrand factor, collagen, fibronectin, and laminin) or occurs through the epinephrine, for instance. It is of paramount importance to note that the molecules present in the endothelium are also expressed in other cell types, as demonstrated by Monteiro: the glycoprotein GPIb alpha (present in platelet membranes and exerting the function of mediator of the adhesion to the von Willebrand factor in the vascular endothelium) was also detected in the membrane of dermal cells known as dermal dendrocytes.

The presence of receptors of platelets in the membrane of dermal cells may indicate the participation of these cells in wound healing and repair processes.

It is important to remember that the skin houses different types of stem cells (including cells present in the hair follicle bulge) and cells of mesenchymal origin, all dispersed in the dermis. In theory, growth factors released by platelets could act in these cells, promoting differentiation and proliferation. This information should be taken into account when planning to achieve a specific goal with the use of PRP in the skin.

In Table 1 there are descriptions of some of the functions of growth factors released during platelet activation.

**Applications in dermatology**

The use of PRP in medicine is based on the fact that platelets contain many growth factors in their alpha granules. These factors have a well-known role in the process of tissue repair. Thus, the concentration of these substances in injured tissues could be beneficial to providing more agility to the regeneration processes.

**Alopecia**

The application of PRP in the treatment of alopecia has been investigated with renewed interest in recent years. Some studies seek to establish the molecular mechanisms through which such patients could benefit from PRP. In an *in vitro* and *in vivo* study in animals, Li *et al.* showed that there is a greater proliferation of dermal papilla cells when incubated with PRP, as compared to controls. That effect was due to increased expression of FGF-7 (Fibroblast growth factor 7) and β-catenin, as well as an increase in extracellular signaling of Akt and ERK.

The animals that received subcutaneous injections of PRP had a faster transition from the telogen to the anagen phase as compared to the controls, which received only saline injections. The study by Li *et al.* indicates the molecular mechanisms through which these results were found, reinforcing the importance of further investigations into the use of PRP for this indication. This study presents LOE 5, given that it is based on physiological mechanisms in animals and cell cultures (Chart 2).

In a study published in 2006, Uebel described an apparent improvement in survival rates and take in hair grafts that were exposed to PRP before implantation, as compared to contralateral controls, in a group of 20 male patients. The limitation of this study is linked to the fact that the interpretation of the results was not carried out by independent researchers and also because the area that received the implants treated with PRP was not clearly defined. This study has a LOE 4.

**Wound healing**

The use of PRP to accelerate the healing of wounds inspires the greatest number of clinical studies. Publications address various issues, such as its use in the treatment of chronic wounds in diabetic patients, in the assessment of the speed of re-epithelialization of donor sites in skin grafting, and in the closing of chronic ulcers due to vascular insufficiency, among others.

Two systematic reviews of randomized controlled trials on the use of PRP in the treatment of chronic wounds led to differing conclusions.

After the evaluation of nine clinical trials, Sommeling *et al.* considered that the use of PRP may be beneficial as an adjuvant measure in the treatment of chronic ulcers. Nevertheless, the authors highlight the poor quality of the trials used in the review and the lack of standardization in the methods employed to obtain the PRP and the manner in which it was used.

In a review conducted by Cochrane, nine studies were included, totaling 325 treated patients. The authors conducted an analysis of randomized, controlled trials that compared the use of PRP versus a placebo or alternative therapies in the treatment of chronic ulcers (of any etiology) in adults. The studies were selected based on previously defined criteria, such as patient selection, data collection, and risk of bias. After the evaluation of these studies by two independent authors, it was concluded that there was no evidence in favor of the use of PRP in the treatment of ulcers, when compared to placebo or other alternatives. However, due to the small number of studies included in the review, some of them with a risk of bias, the authors suggest that more encompassing and more well-formatted studies were necessary.
According to the Oxford CEBM classification, systematic reviews of randomized controlled trials correspond to LOE 1.

**Laser**

There are few reports on the association of laser treatments and a concomitant application of PRP. In these studies, a small number of patients underwent treatment with a fractional laser (1,550nm and 10,600nm wavelengths).

In a study by Shin, 22 patients were treated with a 1,550nm laser, with only half of them receiving topical applications of PRP following the laser sessions. At the end of the study, the group treated with the combination of laser and PRP showed less erythema and greater subjective satisfaction. The authors’ conclusion does not suggest a clear superiority of the combined approach as compared to the isolated application of fractional laser.

In two studies that combine the applications of fractional CO2 laser and PRP (injected intradermally or applied topically after the laser) there was faster recovery of post-laser edema and erythema as well better outcomes (assessed subjectively) when compared to patients who did not receive this treatment.

As with other applications, there was no standardization in the method for obtaining PRP in this case.

These studies are defined as LOE 4.

**Rejuvenation**

There are few published clinical studies regarding the use of PRP for rejuvenation purposes, with most of them not clearly describing the method for obtaining PRP, nor clarifying the content of the material obtained. As noted earlier, these data have a fundamental impact on the evaluation of results. Furthermore, many of the studies do not have control groups, and others have only photographic images and the subjective impressions of researchers and patients on the final results, as the only method of assessing results. Those studies have LOE 4.

Studies that have used animals or cellular cultures have LOE 5.

The introduction of PRP into the culture medium of human dermal fibroblasts led to an increased proliferation of these cells, as well as to an increased production of collagen in comparison to control cultures that were not incubated with PRP. Likewise, the culture of stem cells derived from adipose tissue in a medium containing PRP also led to the increased proliferation of these cells. This finding reinforces the possibility of PRP interfering with the biology of stem cells present in the skin. A similar study carried out in animals showed similar results.

**Annex: Levels of Scientific Evidence**

Evidence-based medicine is a concept that unites good scientific research and clinical practice. The practice of this kind of medicine assumes that the choice among therapeutic interventions should be based on the hierarchy of evidence available at the time, among other criteria. This does not mean that the physician’s professional experience should not be taken into account, but that good scientific research can help enormously in making therapeutic decisions.

Chart 2 presents a summarized scheme of the LOEs proposed by the Oxford Centre for Evidence-Based Medicine, which must be understood in conjunction with the accompanying introductory document. These LOEs relate solely to issues related to treatment.

The Brazilian Ministry of Health adopts this classification in their technical opinions.
REFERENCES


